ClinicalTrials.gg
Active, not recruitingNCT05814159Updated Mar 5, 2025

A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)

A Phase 3 interventional study of Anakinra and Placebo in Still's Disease, Juvenile Onset and Still's Disease, Adult-Onset, sponsored by Swedish Orphan Biovitrum. Active, not recruiting at 8 sites in Japan. Open to participants aged 8 Months and older. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by Swedish Orphan Biovitrum · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
8 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Arthritis, Juvenile with a site in Japan — 3 open to participants now, 6 under way, 5 of them phase 3. Arthritis, Juvenile · Japan.

Enrollment
11th of 11
15 · median 58
Started
2022
the only one that year
Phase 3
10 of 12
3 open now
Registered
11th of 12
by date
Lead sponsor
2 of 12
Swedish Orphan Biovitrum

Among the 12 studies in Arthritis, Juvenile with a site in Japan, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2022, is one of 10 in phase 3, and was the 11th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

3 of the 12 studies in Arthritis, Juvenile with a site in Japan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.

This study: 8 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Arthritis, Juvenile with a site in Japan, or all of them as a file.
02

Study summary

A study to demonstrate efficacy and safety of anakinra in pediatric and adult Japanese patients with Still's disease (Systemic juvenile idiopathic arthritis [SJIA] and Adult-onset Still's disease [AOSD]).

Read the detailed description

The study consists of two phases:

  • Core phase comprising 2 weeks double blind placebo-controlled treatment, 52 weeks open label treatment and 4 weeks safety follow up (only for patients not entering the extension phase).

At the Week 54 visit, patients who consent and are eligible to continue anakinra treatment, will enter the extension phase and continue open label anakinra treatment.

  • Extension phase comprising up to 26 weeks open label treatment and 4 weeks safety follow up.

The primary endpoint will be evaluated at Week 2 visit.

03

Conditions studied

  • Still's Disease, Juvenile Onset
  • Still's Disease, Adult-Onset
04

Who can participate

Ages eligible
8 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male and female patients, 8 months of age or older with a body weight ≥ 10 kg
  2. Diagnosis of Still's disease
  3. If \< 16 years of age at disease onset, the diagnosis is madeaccording to adapted ILAR criteria i.e., CARRA criteria for SJIA. If ≥ 16 years of age at disease onset, the diagnosis is made according to Yamaguchi criteria for AOSD.
  4. Active disease confirmed by the following three signs and symptoms. a. Active arthritis in ≥ 1 joint. b. CRP > 30 mg/L. c. At least one fever episode (≥ 38.0 degree Celsius) attributable to the disease within one week before enrollment.
  5. The result of tuberculosis test within 8 weeks prior to enrollment is negative.

Key Exclusion Criteria:

  1. Previous or current treatment with anakinra, or any other Interleukin-1 (IL-1) inhibitor except for canakinumab. Previous treatment with canakinumab is allowed if canakinumab was discontinued for reasons other than lack of efficacy and after a of minimum 130 days. Patients who have discontinued canakinumab because of insufficient effect or disease are not allowed to be enrolled in the study.
  2. Use of the following therapies prior to enrollment.

    1. Narcotic analgesics within 24 hours prior to enrollment.
    2. Diaminodiphenyl sulfone within 1 week prior to enrollment or etanercept within 2 weeks prior to enrollment.
    3. Intraarticular, intramuscular, or intravenous administration of within 72h(3 days) prior to enrollment, or intravenous immunoglobulin within 4 weeks prior to enrollment.
    4. Intravenous immunoglobulins with proven Still's disease modifying effect, leflunomide, infliximab, or adalimumab within 8 weeks prior to enrollment.
    5. Thalidomide within 72h(3 days) prior to enrollment, cyclosporine within 5 weeks prior to enrollment, mycophenolate mofetil within 1 week prior to enrollment, 6-mercaptopurine within 48h(2 days) prior to enrollment, azathioprine within 72h(3 days) prior to enrollment, cyclophosphamide within 96h(4 days) prior to enrollment, chlorambucil (not approved inJapan) within 48h(2 days) prior to enrollment, or any other within 12 weeks prior to enrollment.
    6. Tocilizumab within 4 weeks prior to enrollment or any other immunomodulatory medications within 4 half-lives prior to enrollment.
    7. Rituximab within 13 weeks prior to enrollment.
    8. Canakinumab within 130 days prior to enrollment
  3. within 4 weeks prior to enrollment.
  4. Known presence or suspicion of active, chronic, or recurrent bacterial, fungal, or viral infections, including but not limited to tuberculosis, infection, Covid-19 infection, or or C infection at baseline. Patients with acute or chronic HBV.
  5. Clinical evidence of liver disease or liver injury as indicated by presence of abnormal liver tests.
  6. Presence of severe chronic kidney disease (CKD) grades 4 and 5.
  7. Presence of neutropenia ( [ANC] \< 1.5 x 10\^9/L).
  8. Presence of thrombocytopenia ( count \< 100 x 10\^9/L).
  9. Presence or suspicion of MAS at baseline.
  10. History or diagnosis of MAS within the last 4 weeks prior to enrollment.

After completion of the study Core Phase, patients who consent and are eligible to continue anakinra treatment, can enter the extension phase .

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Anakinra

    100 mg/day or 2 mg/kg/day of subcutaneous anakinra for those with a body weight ≥50 kg or \<50 kg, respectively.

    Drug: Anakinra

  • Placebo comparator
    Placebo

    Corresponding volume to 100 mg/day or 2 mg/kg/day

    Drug: Placebo

Interventions

  • sub cutaneous daily injection

    Also known as: Kineret

  • DrugPlacebo

    sub cutaneous daily injection

06

What researchers measure

Primary outcomes

  1. An improvement of ≥ 30% from baseline in physician global assessment of disease activity (visual analogue scale [VAS]).

    ACR30 response with absence of fever attributable to the disease during the 7 days

    Time frame: Week 2

  2. An improvement of ≥ 30% from baseline in patient/parent global assessment of overall well-being (VAS).

    ACR30 response with absence of fever attributable to the disease during the 7 days

    Time frame: Week 2

  3. An improvement of ≥ 30% from baseline in number of joints with active arthritis.

    ACR30 response with absence of fever attributable to the disease during the 7 days

    Time frame: Week 2

  4. An improvement of ≥ 30% from baseline in number of joints with limitation of motion.

    ACR30 response with absence of fever attributable to the disease during the 7 days

    Time frame: Week 2

  5. An improvement of ≥ 30% from baseline in assessment of physical function: Child health assessment questionnaire (CHAQ)/Stanford health assessment questionnaire (SHAQ).

    ACR30 response with absence of fever attributable to the disease during the 7 days

    Time frame: Week 2

  6. An improvement of ≥ 30% from baseline in C-reactive protein (CRP) (mg/L).

    ACR30 response with absence of fever attributable to the disease during the 7 days

    Time frame: Week 2

Secondary outcomes

  1. Change in CRP.

    To demonstrate the efficacy of anakinra compared to placebo in reducing inflammation in Still's disease.

    Time frame: Week 2

  2. Change in ferritin.

    To demonstrate the efficacy of anakinra compared to placebo in reducing inflammation in Still's disease.

    Time frame: Week 2

  3. Change in haemoglobin.

    To demonstrate the efficacy of anakinra compared to placebo in reducing inflammation in Still's disease.

    Time frame: Week 2

  4. Change in platelets count.

    To demonstrate the efficacy of anakinra compared to placebo in reducing inflammation in Still's disease.

    Time frame: Week 2

  5. Change in white blood cells count.

    To demonstrate the efficacy of anakinra compared to placebo in reducing inflammation in Still's disease.

    Time frame: Week 2

  6. Absence of fever during the 24 hours preceding the evaluation visit at Week 1.

    To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.

    Time frame: Week 1

  7. Absence of rash during the 24 hours preceding the evaluation visit at Week 1.

    To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.

    Time frame: Week 1

  8. ACR30 response with absence of fever during the 24 hours preceding the evaluation visit at Week 1.

    To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.

    Time frame: Week 1

  9. ACR50 response with absence of fever during the 24 hours preceding the evaluation visit at Week 1.

    To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.

    Time frame: Week 1

  10. ACR70 response with absence of fever during the 24 hours preceding the evaluation visit at Week 1.

    To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.

    Time frame: Week 1

  11. Change in physician global assessment of disease activity, measured on a VAS from no pain (0 mm) to very severe (100 mm).

    To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.

    Time frame: Week 1

  12. Change in patient/parent global assessment of overall well-being, measured on a VAS from no pain (0 mm) to very severe (100 mm).

    To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.

    Time frame: Week 1

  13. Change in patient/parent global assessment of disease related pain, measured on a VAS from no pain (0 mm) to very severe (100 mm).

    To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.

    Time frame: Week 1

  14. Change in swelling joints count.

    To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.

    Time frame: Week 1

  15. Change in tender joints count.

    To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.

    Time frame: Week 1

  16. Change in CRP.

    To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.

    Time frame: Week 1

  17. Change in ferritin.

    To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.

    Time frame: Week 1

  18. Change in haemoglobin.

    To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.

    Time frame: Week 1

  19. Change in platelets count.

    To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.

    Time frame: Week 1

  20. Change in white blood cells count.

    To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.

    Time frame: Week 1

  21. Change in the number/proportion of patients reporting problems by dimension of EQ-5D-Y Proxy (4-7 years).

    To evaluate and compare the health status between anakinra treated patients and patients treated with placebo.

    Time frame: Week 2

  22. Change in the number/proportion of patients reporting problems by dimension of EQ-5D-Y (8-15 years).

    To evaluate and compare the health status between anakinra treated patients and patients treated with placebo.

    Time frame: Week 2

  23. Change in the number/proportion of patients reporting problems by dimension of EQ-5D-3L (≥ 16 years).

    To evaluate and compare the health status between anakinra treated patients and patients treated with placebo.

    Time frame: Week 2

  24. Absence of fever during the 7 days preceding the visit.

    To evaluate efficacy of anakinra in Still's disease.

    Time frame: Week 4 to Week 54

  25. Absence of rash during the 7 days preceding the visit.

    To evaluate efficacy of anakinra in Still's disease.

    Time frame: Week 4 to Week 54

  26. ACR30 response with absence of fever during the 7 days preceding the visit.

    To evaluate efficacy of anakinra in Still's disease.

    Time frame: Week 4 to Week 54

  27. ACR50 response with absence of fever during the 7 days preceding the visit.

    To evaluate efficacy of anakinra in Still's disease.

    Time frame: Week 4 to Week 54

  28. ACR70 response with absence of fever during the 7 days preceding the visit.

    To evaluate efficacy of anakinra in Still's disease.

    Time frame: Week 4 to Week 54

  29. ACR90 response with absence of fever during the 7 days preceding the visit.

    To evaluate efficacy of anakinra in Still's disease.

    Time frame: Week 4 to Week 54

  30. Change in physician global assessment of disease activity (VAS).

    To evaluate efficacy of anakinra in Still's disease.

    Time frame: Week 4 to Week 54

  31. Change in patient/parent global assessment of overall well-being (VAS).

    To evaluate efficacy of anakinra in Still's disease.

    Time frame: Week 4 to Week 54

  32. Change in patient/parent global assessment of disease related pain (VAS).

    To evaluate efficacy of anakinra in Still's disease.

    Time frame: Week 4 to Week 54

  33. Change in swelling joints count.

    To evaluate efficacy of anakinra in Still's disease.

    Time frame: Week 4 to Week 54

  34. Change in tender joints count.

    To evaluate efficacy of anakinra in Still's disease.

    Time frame: Week 4 to Week 54

  35. Change in CRP.

    To evaluate efficacy of anakinra in Still's disease.

    Time frame: Week 4 to Week 54

  36. Change in ferritin.

    To evaluate efficacy of anakinra in Still's disease.

    Time frame: Week 4 to Week 54

  37. Change in haemoglobin.

    To evaluate efficacy of anakinra in Still's disease.

    Time frame: Week 4 to Week 54

  38. Change in platelets count.

    To evaluate efficacy of anakinra in Still's disease.

    Time frame: Week 4 to Week 54

  39. Change in white blood cells count.

    To evaluate efficacy of anakinra in Still's disease.

    Time frame: Week 4 to Week 54

  40. Occurrence of inactive disease.

    Proportion of patients who reach inactive disease.Inactive disease is defined as no joints with active arthritis, no fever, no rash, serositis, no hepatosplenomegaly, no generalized lymphadenopathy attributable to Still's disease, CRP level within normal limits, physician's global assessment of disease activity score below 10 mm on a 100 mm VAS, and a documented morning stiffness ≤15 min.

    Time frame: Week 8 to Week 54

  41. Change in the number/proportion of patients reporting problems by dimension of EQ-5D-Y Proxy (4-7 years).

    To evaluate the health status in anakinra treated patients with Still's disease.

    Time frame: Week 4 to Week 54

  42. Change in the number/proportion of patients reporting problems by dimension of EQ-5D-Y (8-15 years).

    To evaluate the health status in anakinra treated patients with Still's disease.

    Time frame: Week 4 to Week 54

  43. Change in the number/proportion of patients reporting problems by dimension of EQ-5D-3L(≥ 16 years).

    To evaluate the health status in anakinra treated patients with Still's disease.

    Time frame: Week 4 to Week 54

  44. ACR30 response with absence of fever during the 7 days preceding the study visits over time.

    To evaluate sustained efficacy of anakinra in patients responding to study drug.

    Time frame: Week 2 to Week 54

  45. To evaluate the occurrence of study drug discontinuation in anakinra treated patients with Still's disease.

    * Time to study drug discontinuation due to lack of efficacy or progressive disease. * Time to study drug discontinuation due to any reason. * Number of patients discontinuing study treatment.

    Time frame: Day 1 to Week 54

  46. Time of initiation of glucocorticoids tapering.

    To evaluate glucocorticoids tapering in anakinra treated patients with Still's disease.

    Time frame: Week 2 to Week 54

  47. Percentage decrease of glucocorticoids dose for patients tapering their glucocorticoids dose.

    To evaluate glucocorticoids tapering in anakinra treated patients with Still's disease.

    Time frame: Week 2 to Week 54

  48. Discontinuation of glucocorticoids.

    To evaluate glucocorticoids tapering in anakinra treated patients with Still's disease.

    Time frame: Week 2 to Week 54

  49. - Occurrence of adverse events (AEs) (serious adverse events [SAEs] and non-SAEs).

    To evaluate the safety of anakinra in patients with Still ́s disease.

    Time frame: Baseline to Week 58

  50. Occurrence of deaths

    To evaluate the safety of anakinra in patients with Still ́s disease.

    Time frame: Baseline to Week 58

  51. Occurrence of AEs leading to study drug discontinuation at all study visits.

    To evaluate the safety of anakinra in patients with Still ́s disease.

    Time frame: Baseline to Week 58

  52. Occurrence of vital signs changes from baseline, including blood pressure, heart rate, and body weight at all study visits up to Week 58 visit. Changes of height in patients younger than 19 years old.

    To evaluate the safety of anakinra in patients with Still ́s disease.

    Time frame: Baseline to Week 58

  53. Occurrence of laboratory safety assessments changes over time.

    To evaluate the safety of anakinra in patients with Still ́s disease.

    Time frame: Baseline to Week 58

  54. Occurrence of abnormal laboratory values.

    To evaluate the safety of anakinra in patients with Still ́s disease.

    Time frame: Baseline to Week 58

  55. To evaluate immunogenicity of anakinra in patients with Still's disease.

    * Occurrence of ADAs, NAbs, cross-reactivity, and titer levels of ADAs and NAbs * Occurrence and titer levels of ADAs in relation to AEs * Occurrence and titer levels of ADAs, NAbs cross-reactivityin relation to ACR30 response and CRP levels

    Time frame: Baseline, Weeks 2, 4, 12, 34, 54 and 58

  56. To evaluate the pharmacokinetic of anakinra in patients with Still's disease

    Anakinra serum concentrations

    Time frame: Baseline, Weeks 1 and 2

07

Study locations

8 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Dec 2025, 39 months after the start.

Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's planned 39 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2022
First posted
Apr 14, 2023
StartActual
Aug 24, 2022
Primary completionEst.
Dec 10, 2025
CompletionEst.
Jun 24, 2026
Last update
Mar 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05814159
Collaborators
CMIC Co, Ltd. Japan
Responsible party
Sponsor
First posted
Apr 14, 2023
Start date
Aug 24, 2022
Primary completion
Dec 10, 2025 (estimated)
Completion
Jun 24, 2026 (estimated)
Last update
Mar 5, 2025

Study contacts

Masaaki Mori, MD
principal investigator · St. Marianna University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interleukin 1 Receptor Antagonist Protein

Start the discussion